As public spats go, this one is going to take some beating. St. Jude is not looking like its in the mood to give up as it comes right back at Medtronic, Dr Hauser and Heart Rhythm.
Medtronic
Heart Rhythm Says No To St.Jude Request
Predictaresponse time. Heart Rhythm has refused to retract, which it was always likely to do. St. Jude might get the chance to respond in public as the journal offers to review its data.
Now FDA Expands Indication For Medtronic’s CRT-D Devices To Treat Mildly Symptomatic Heart Failure Patients
Medtronic declares itself pleased, but in reality must be absolutely delighted by the news that FDA has allowed it to expand the indications for its CRT-D resynchronisation/defibrillator devices to now include patients with mildly symptomatic heart failure.
Riata: Medtronic Joins War Of Words
It’s all getting a bit heated as Medtronic and St. Jude lock horns again, this time over the Hauser publication in Heart Rhythm journal.
St Jude Questions Hauser Paper And Demands Retraction
According to St Jude, Dr Robert Hauser’s paper, accepted for publication in the Heart Rhythm Journal is biased and inaccurate, comparing apples with pears and peddling conclusions it’s own analysis cannot reproduce from the data set. Watch this space.
Heart Blog Rather Sums It All Up
Thoughtful and insightful blog post from today on theheart.org
Medtronic Settles Shareholder Class Action Over Infuse
Medtronic settles its shareholder class action lawsuit for $85M.
Medtronic’s Renal Denervation Therapy Treats Hypertension for Years
Two studies presented at ACC 2012 suggest that Medtronic’s Symplicity System for renal denervation shows safe, sustained and significant blood pressure reduction in treatment-resistant hypertension patients.
Positive Clinical Outcomes From Medtronic’s CoreValve® Study Data
Medtronic announces strong clinical outcomes for its Corevalve product at ACC meeting.
Everolimus Shines As Meta-Analysis Suggests Lower Thrombosis Rates Than Others
Everolimus stents appear top dog in long term stent thrombosis meta-analysis.
CE Mark For Medtronic’s CD Horizon BalanC™Spinal System
Medtronic gains CE Mark approval for its CD HORIZON BalanC™ Spinal Fusion System, promising a new level of adaptablity to patient anatomy.
Canada Approves Medtronic’s DBS For Epilepsy And Boston’s Cardiac Ablation System
Two new device approvals announced for Canada this week. Neither Medtronic’s DBS therapies for epilepsy nor Boston Scientific’s RF ablation catheter are US FDA approved, but Health Canada are clearly convinced by the weight of the submissions.
First Patient Enrolled In European Deep Brain Stimulation Registry For Refractory Epilepsy
Deep Brain Stimulation for Refractory Epilepsy: First patient enrolled in Netherlands some 25 years after DBS was first indicated for essential tremor.
Left Atrial Appendage Occlusion Devices Will Challenge Anticoagulants, Germany Report Suggests
Will MRG’s report into growth in the German Left Atrial Appendage Occlusion market be a best seller. Bit nichey perhaps, but an indicator of the potential for the procedure.
CE Mark For PARADISE™ Ultrasound Transcatheter Renal Denervation System
Initial results of ReCor’s REDUCE First-In-Man clinical study presented at “TRenD 2012” transcatheter renal denervation scientific meeting as company gains CE mark for its PARADISE™ system.
Medtronic Revenues And Earnings Holding Up
Solid figures, but it’s not quite all good news at Medtronic as sales in some divisions suffer, especially in USA.